Pharma-Bio Serv, Inc. (PBSV) Stock Forecast Oct. 16, 2026
Analysis updated on Oct. 16, 2026 (UTC) · Alpha · vs marketSwitch to Total · OTC
Pharma-Bio Serv, Inc. (PBSV) stock forecast summary
Our AI ranks Pharma-Bio Serv, Inc. outside the neutral middle of its coverage (a directional signal). Create a free account and follow it to see the exact price target.
Pharma-Bio Serv, Inc. is a small-cap company with a market capitalization of $9M. It ranks number 31 by market capitalization among the 37 Services-Management Consulting Services issuers in our coverage with a current forecast.
For PBSV, the Spearman rank correlation between our 90-day forecasts and the returns that followed is -29.0%, measured on 357 forecast dates between 2022-07-29 and 2026-07-17 on this stock's own recent history. A rank correlation runs from -100% to +100%: it measures whether higher forecasts were followed by higher returns, and a value near zero or below means the model has shown little skill on this stock. On the 30-day forecasts the same correlation is -23.0%, measured on 400 forecast dates between 2022-07-29 and 2026-09-16. Across our coverage, the out-of-sample test on 4495 stocks from 2025-01-06 to 2026-07-07 produced a positive net return in 82.5% of rebalance periods (factor-neutral book, net of estimated costs). Full backtest report
Expected return relative to the market over the horizon: a positive alpha means the model expects the stock to beat the market, whatever the market does. Ratings: strong buy ≥ +1.8%, buy ≥ +0.2%, sell < -0.9%, strong sell < -1.2% (top 15%, next 20%, middle 30%, next 20%, bottom 15% of the 2026-10-16 signals)
A free account shows the exact forecast, rating and rank of 3 tickers you follow, PBSV included.
Follow PBSV freePBSV price chart and AI forecast
How PBSV ranks among 5184 stocks
90D Alpha forecasts of every company scored, cut into five relative ratings at the 15th, 35th, 65th and 85th percentiles (dashed lines).
Pharma-Bio Serv, Inc. (PBSV) fundamentals
Trailing twelve months. The industry median and the rank (1 = highest) are taken over the Services-Management Consulting Services peers listed below that report each metric.
Valuation & Market
| Metric | PBSV | Rank |
|---|---|---|
| Market Cap | $9M | 31/37 |
| P/B Ratio | 0.88x | 25/30 |
| EPS | $-0.01 | – |
| Book Value/Share | $0.46 | – |
| Revenue/Share | $0.41 | – |
| FCF/Share | $-0.02 | – |
Profitability & Margins
| Metric | PBSV | Rank |
|---|---|---|
| ROE | 2.4% | 15/23 |
| ROA | 2.2% | 14/29 |
| ROIC | -1.5% | 21/30 |
| Gross Margin | 32.3% | 17/25 |
| Operating Margin | -1.6% | 18/32 |
| Net Margin | 2.6% | 13/27 |
| EBT Margin | 2.8% | 15/34 |
| Tax Rate | 2.9% | – |
Financial Health
| Metric | PBSV | Rank |
|---|---|---|
| Current Ratio | 11.30x | 4/35 |
| D/E Ratio | 0.10x | 29/33 |
| Financial Leverage | 1.10x | 29/33 |
| Interest Coverage | 479.7x | 1/30 |
| Working Capital | $10M | 18/35 |
Cash Flow
| Metric | PBSV | Rank |
|---|---|---|
| Operating Cash Flow | -$410K | 28/39 |
| Free Cash Flow | -$420K | 17/19 |
| Capital Spending | -$10K | 2/19 |
| FCF/Sales | -4.4% | 16/19 |
| CapEx/Sales | 0.1% | 18/19 |
Operational Efficiency
| Metric | PBSV | Rank |
|---|---|---|
| Asset Turnover | 0.83x | 18/27 |
| Receivables Turnover | 3.9x | 15/19 |
| Fixed Assets Turnover | 118.5x | 4/21 |
| Days Sales Outstanding | 93 days | 5/20 |
| Payables Period | 53 days | 10/21 |
Income Statement
| Metric | PBSV | Rank |
|---|---|---|
| Total Revenue | $9M | 19/28 |
| Operating Income | -$150K | 24/37 |
| Net Income | $250K | 16/30 |
| SG&A Expense | $3M | 14/19 |
| Cost of Goods Sold | $6M | 16/28 |
Dividend & Shareholder Information
| Metric | PBSV | Rank |
|---|---|---|
| Shares Outstanding | 23M | – |
Balance Sheet Highlights (USD millions)
| Total Current Assets | $11M | 98.6% of assets |
| Cash & Short-term Investments | $2M | 13.3% of assets |
| Accounts Receivable | $2M | 21.2% of assets |
| Total Liabilities | $990K | 8.7% of assets |
| Short-term Debt | $70K | 0.6% of assets |
PBSV quarterly financials and insider trading
Pharma-Bio Serv, Inc. (PBSV) industry peers
Companies classified under the same SEC industry code as Pharma-Bio Serv, Inc. (Services-Management Consulting Services): 45 common-stock issuers with a forecast this week, one row per issuer, largest first. This is a classification match, not a curated list of competitors.
Reveal all forecasts · See exact % predictions for all competitors
Sign up free| Company | 90-Day AI Forecast (Alpha) | Market Cap |
|---|---|---|
| PBSV Pharma-Bio Serv, Inc. | ▲ | $9M |
| GIB Cgi Inc | ▶ | $16.57B |
| BAH Booz Allen Hamilton Holding Corp | ▼ | $8.93B |
| G Genpact Ltd | ▼ | $6.26B |
| FCN Fti Consulting, Inc | ▼ | $4.10B |
| EXPO Exponent Inc | ▶ | $3.42B |
| HURN Huron Consulting Group Inc. | ▶ | $3.01B |
| ASTH Astrana Health, Inc. | ▶ | $2.05B |
| ICFI Icf International, Inc. | ▼ | $1.60B |
| BWMN Bowman Consulting Group Ltd. | ▼ | $741M |
| RMR Rmr Group Inc. | ▲ | $587M |
| ONT Onterris, Inc. | ▲ | $492M |
| ROMA Roma Green Finance Ltd | ▶ | $478M |
| PPHC Public Policy Holding Company, Inc. | ▲ | $310M |
| HCKT Hackett Group, Inc. | ▼ | $281M |
| III Information Services Group Inc. | ▶ | $274M |
| TSSI Tss, Inc. | ▼ | $200M |
| PHCI Panamera Holdings Corp | ▼ | $169M |
| RTB Rtb Digital, Inc. | ▼ | $109M |
| AUC Atif Holdings Ltd | ▲ | $90M |
| GFLT Genflat Holdings, Inc. | ▼ | $78M |
| MHH Mastech Digital, Inc. | ▶ | $76M |
| VDTA Vertical Data Inc. | ▶ | $56M |
| CTM Castellum, Inc. | ▶ | $55M |
| EUBG Entrepreneur Universe Bright Group | ▶ | $43M |
| AERT Aeries Technology, Inc. | ▶ | $33M |
| RYOJ Ryojbaba Co., Ltd. | ▼ | $30M |
| ACCS Access Newswire Inc. | ▲ | $18M |
| DFNS T3 Defense Inc. | ▼ | $14M |
| LICN Lichen International Ltd | ▼ | $14M |
| GRNQ Greenpro Capital Corp. | ▶ | $14M |
| CISO Ciso Global, Inc. | ▲ | $8M |
| ELVG Elvictor Group, Inc. | ▶ | $5M |
| BDTB Bodhi Tree Biotechnology Inc | ▼ | $5M |
| YSGL Yellowstone Group Ltd. | ▼ | $3M |
| RDSC Radiant Strategies Corp | ▼ | $1M |
| HSTA Hestia Insight Inc. | ▶ | $840K |
| GXXM Gex Management, Inc. | ▼ | N/A |
| IVHI Invech Holdings, Inc. | ▲ | N/A |
| LEEN Leopard Energy, Inc. | ▼ | N/A |
| NORD Nordicus Partners Corp | ▶ | N/A |
| SATT Sativus Tech Corp. | ▶ | N/A |
| SSHT Ssht S&T Group Ltd. | ▼ | N/A |
| THRC Havana Roasters Coffee Companies, Inc. | ▼ | N/A |
| WYGC Wenyuan Group Corp. | ▼ | N/A |
Where PBSV sits on the market map
Pharma-Bio Serv, Inc. (PBSV) stock news
Loading...
Pharma-Bio Serv, Inc. (PBSV) stock forecast FAQ
What is the Pharma-Bio Serv, Inc. (PBSV) stock forecast?
Our AI ranks Pharma-Bio Serv, Inc. outside the neutral middle of its coverage (a directional signal). Create a free account and follow it to see the exact price target.
How accurate are Pharma-Bio Serv, Inc. stock predictions?
For PBSV, the Spearman rank correlation between our 90-day forecasts and the returns that followed is -29.0%, measured on 357 forecast dates between 2022-07-29 and 2026-07-17 on this stock's own recent history. A rank correlation runs from -100% to +100%: it measures whether higher forecasts were followed by higher returns, and a value near zero or below means the model has shown little skill on this stock. On the 30-day forecasts the same correlation is -23.0%, measured on 400 forecast dates between 2022-07-29 and 2026-09-16. Across our coverage, the out-of-sample test on 4495 stocks from 2025-01-06 to 2026-07-07 produced a positive net return in 82.5% of rebalance periods (factor-neutral book, net of estimated costs). Full backtest report
How often are Pharma-Bio Serv, Inc. forecasts updated?
Pharma-Bio Serv, Inc. forecasts are refreshed on trading days as the daily model run completes. The forecast on this page was produced on Oct. 16, 2026.
Which companies are Pharma-Bio Serv, Inc.'s industry peers?
45 issuers in our coverage, PBSV included, share the SEC industry code Services-Management Consulting Services. The largest are: Cgi Inc (GIB), Booz Allen Hamilton Holding Corp (BAH), Genpact Ltd (G), Fti Consulting, Inc (FCN), Exponent Inc (EXPO), Huron Consulting Group Inc. (HURN).
This analysis is generated automatically using our proprietary AI systems and should not be considered personalized investment advice. Past performance does not guarantee future results. Always conduct your own research and consider consulting a financial advisor before making investment decisions.